UNSPSC 51384532: Naproxen piperazine

This classification denotes a cyclooxygenase inhibitor 2C14H14O3.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R2A8B8HIPI, chemically known as (s)-6-methoxy-.alpha.-methylnaphthalene-2-acetic acid, compound with piperazine (2:1), but more generally known as naproxen piperazine, which bears US NIH Compound Identifier 155581. Most nations, for tariff and trade purposes, schedule naproxen piperazine under HS 29189900 and SITC 51396. As of Q4 2014, NAPROXEN PIPERAZINE remains US FDA's Preferred Term for this commodity.

SMILES: C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)O.C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)O.C1CNCCN1.

UNSPSC 51384532 Naproxen piperazine is a Commodity code nominally tracking a specific anti-inflammatory pharmaceutical, but recent state and local solicitations show the code tagged to a much broader range of pharmaceutical procurement activities including naloxone, generic multi-source drugs, over-the-counter products, and direct-to-manufacturer prescription programs. State and local governments buying under this code are pursuing inventory replenishment and program-level pharmaceutical supply agreements to support public health, emergency response, and employee benefit programs. Issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state and local facilities across participating states including Oregon).

Activity concentrates in Florida, Texas, and Minnesota with signs of broader multi-state reach through cooperative purchasing vehicles. The Seminole County Health Department issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and quarterly delivery to a county health building; the contract includes a two-year initial term with a one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels, signaling early-stage exploration of alternative pharmaceutical supply mechanisms. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026, response deadline, to establish multi-year contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson); awarded vendors must comply with current Good Manufacturing Practices and Drug Supply Chain Security Act certification and maintain $2 million to $5 million in commercial general liability and specialized insurance coverage.